Pfizer Acquires Metsera for $10 Billion, Leading Obesity Treatment Market

Pfizer Wins $10 Billion Bidding War to Acquire Metsera

New York, 8 November 2025 — American pharmaceutical giant Pfizer Inc. has announced that it has won the $10 billion bidding war to acquire the U.S.-based biotech company Metsera Inc. The deal comes after a fierce competition with Denmark’s Novo Nordisk A/S.

Metsera is a biotech startup focused on developing new therapies for obesity and diabetes. Pfizer offered $86.25 per share, including a cash component of $65.60 per share and an additional $20.65 per share contingent upon the completion of certain research milestones.

Novo Nordisk had also bid approximately $9–10 billion, but Metsera’s board deemed Pfizer’s offer more favorable due to lower regulatory risk and stronger financial assurances. According to the company statement, “Pfizer’s offer represents the most advantageous outcome for our shareholders, while Novo’s bid carried potential legal complexities that made it less acceptable.”

This acquisition is being seen as a major milestone in the global pharmaceutical industry, as the obesity treatment market is rapidly expanding. Experts predict that the sector’s global value could exceed $150 billion over the next decade. Pfizer is set to strengthen its position in this market, especially after its internal research efforts have not produced the desired outcomes.

Although Metsera currently has no commercial drugs on the market, its experimental therapies based on GLP-1 and Amylin hold significant future sales potential. Pfizer aims to advance these drugs quickly to clinical approval to compete with Novo Nordisk and other global players.

Novo Nordisk, acknowledging the setback, stated that it will continue its research initiatives and explore new opportunities. Analysts note that this outcome indicates a growing dominance of U.S. companies in the race for obesity treatment therapies.

Industry analysts predict several key implications of this deal:

Pfizer will immediately gain a foothold in the global obesity treatment market.

Metsera shareholders will receive immediate financial benefits.

Competitive dynamics within the pharmaceutical industry may shift.

Regulatory agencies will play an increasingly important role in future mergers and acquisitions.

This acquisition is not only a competitive investment race between two major companies but also a significant milestone in the global healthcare landscape. The coming months will reveal how rapidly Pfizer brings Metsera’s research products to market and strengthens its position worldwide.